1.Dual rheumatoid factor and anti-cyclic citrullinated peptide antibody positivity affects the manifestations of rheumatoid arthritis.
Li Huan Angela Marie CHAN ; Khai Pang LEONG ; Justina Wei Lynn TAN ; Xiao GAO ; Wei Qiang SEE ; Ee Tzun KOH
Singapore medical journal 2025;66(9):486-491
INTRODUCTION:
Rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibody (ACPA) are used in the diagnosis and prognostication of rheumatoid arthritis (RA). We wanted to determine the specific contributions of RF and ACPA to the biological nature of RA and whether they act synergistically.
METHODS:
We identified 731 patients from our prospective multi-ethnic RA cohort and categorised them into four groups: ACPA-positive, RF-positive, doubly positive and doubly negative. We compared the demographics, Disease Activity Score-28, Health Assessment Questionnaire score, quality of life using Short Form 36 and the use of prednisolone and disease-modifying antirheumatic drugs (DMARDs) of these patient groups.
RESULTS:
Four hundred and ninety-one patients (67.2%) were ACPA+RF+, 54 (7.4%) were ACPA+RF-, 82 (11.2%) were ACPA-RF+ and 104 (14.2%) were ACPA-RF-. Mean disease duration before the study entry was not different in the four groups. Patients with older age of onset were less likely to be positive for RF and ACPA. Fewer ACPA+RF+ patients were in remission compared to those in the other groups ( P < 0.05). Erythrocyte sedimentation rate (ESR) was higher at study entry in the ACPA+RF+ group (40.4 mm/h vs. 30.6-30.9 mm/h, P < 0.05). Prednisolone and number of DMARDs used were higher in the ACPA+RF+ group compared to the doubly negative group. There were no differences in the functional status and quality of life.
CONCLUSIONS
RA patients who were positive for both ACPA and RF had lower remission rate, higher baseline ESR and required more corticosteroid and DMARD treatment compared to those who were singly positive or doubly negative. Being doubly positive confers a worse outcome to RA patients.
Humans
;
Arthritis, Rheumatoid/diagnosis*
;
Male
;
Female
;
Middle Aged
;
Rheumatoid Factor/blood*
;
Anti-Citrullinated Protein Antibodies/blood*
;
Adult
;
Quality of Life
;
Prospective Studies
;
Antirheumatic Agents/therapeutic use*
;
Aged
;
Peptides, Cyclic/immunology*
;
Prednisolone/therapeutic use*
;
Surveys and Questionnaires
;
Severity of Illness Index
;
Prognosis
2.Hydroxychloroquine for COVID-19: A Single Center, Retrospective Cohort Study
Wen Chung Ho ; Wei Xin Yong ; Khai Shin Tan ; Woh Yon Mak ; Mandeep Kaur Gill ; Agnes Hui Ching Lok ; Shazwani Zulkifli ; Salmah Idris ; Khairil Erwan Khalid ; Chee Loon Leong ; Kang Nien How
Malaysian Journal of Medicine and Health Sciences 2023;19(No.2):8-13
Introduction: The outbreak of coronavirus disease (COVID-19) in December 2019 called for a rapid solution, leading to repurposing of existing drugs. Due to its immunomodulatory effect and antiviral properties, hydroxychloroquine (HCQ) has been used in early 2020 for treatment of COVID-19 patients. This study was conducted to evaluate
the treatment outcome of HCQ monotherapy in Malaysia. Methods: A retrospective cohort study was conducted in
COVID-19 ward in Hospital Kuala Lumpur (HKL), from March to April 2020. A total of 446 COVID-19 patients were
recruited, only 325 patients were finally included for analysis. Statistical analysis was done using SPSS, with a significant value set at p<0.05. Results: The mean age of the patients were 38.5 ±15.5. They were majority male, (n=210,
64.6%) Malaysian (n=239, 73.5%) and Malay ethnicity (n=204, 62.8%). Ninety-one (28%) patients received HCQ
monotherapy. HCQ monotherapy was associated with worse outcome (OR: 10.29, 95% CI 1.17-90.80). There was a
significant difference in mean length of stay between those with and without HCQ treatment (t323=5.868, p<0.001,
95% CI, 2.56-5.31). The average length of stay for HCQ treated group was 3.84 days longer than those without
treatment. 6.6% of the patient receiving HCQ monotherapy encountered adverse drug effects. Conclusion: Similar
to study reported worldwide, our study demonstrated that HCQ did not improve length of stay and the outcome of
COVID-19 patients.
3.A Preliminary Experience of Endoscopic Total Mastectomy With Immediate Free Abdominal-Based Perforator Flap Reconstruction Using Minimal Incisions, and Literature Review
Sabrina NGASERIN ; Allen Wei-Jiat WONG ; Faith QI-HUI LEONG ; Jia-Jun FENG ; Yee Onn KOK ; Benita Kiat-Tee TAN
Journal of Breast Cancer 2023;26(2):152-167
Purpose:
Endoscopic total mastectomy (ETM) is predominantly performed with reconstruction using prostheses, lipofilling, omental flaps, latissimus dorsi flaps, or a combination of these techniques. Common approaches include minimal incisions, e.g., periareolar, inframammary, axillary, or mid-axillary line, which limit the technical ability to perform autologous flap insets and microvascular anastomoses, as such the ETM with free abdominal-based perforator flap reconstruction has not been robustly explored.
Methods:
We studied female patients with breast cancer who underwent ETM and abdominal-based flap reconstruction. Clinical-radiological-pathological characteristics, surgery, complications, recurrence rates, and aesthetic outcomes were reviewed.
Results:
Twelve patients underwent ETM with abdominal-based flap reconstruction. The mean age was 53.4 years (range 36–65). Of the patients, 33.3% were surgically treated for stage I, 58.4% for stage II, and 8.3% for stage III cancer. Mean tumor size was 35.4 mm (range 1–67). Mean specimen weight was 458.75 g (range 242–800). Of the patients, 92.3% successfully received endoscopic nipple-sparing mastectomy and 7.7% underwent intraoperative conversion to skin-sparing mastectomy after carcinoma was reported on frozen section of the nipple base. Mean operative time for ETM was 139 minutes (92–198), and the average ischemic time was 37.3 minutes (range 22–50). Fifty percent of patients underwent deep inferior epigastric perforator, 33.4% underwent MS-2 transverse rectus abdominis musculocutaneous (TRAM), 8.3% underwent MS-1 TRAM, and 8.3% underwent pedicled TRAM flap reconstruction. No cases required re-exploration, no flap failure occurred, margins were clear, and no skin or nippleareolar complex ischemiaecrosis developed. In the aesthetic outcome evaluation, 16.7% were excellent, 75% good, 8.3% fair, and none were unsatisfactory. No recurrences were observed.
Conclusion
ETM through a minimal-access inferior mammary or mid-axillary line approach, followed by immediate pedicled TRAM or free abdominal-based perforator flap reconstruction, can be a safe means of achieving an “aesthetically scarless” mastectomy and reconstruction through minimal incisions.
4.Bioprospecting of Endophytic Fungi as Promising Anti-MRSA Agents
Yee-Min WEI ; Joo-Shun TAN ; Hock-Wei TANG ; Woei-Yenn TONG ; Chean-Ring LEONG ; Wen-Nee TAN
Natural Product Sciences 2022;28(3):93-104
Methicillin-resistant Staphylococcus aureus (MRSA) is a serious threat to the global healthcare system. Ineffective and resistance to antibiotic treatments have increased morbidity and mortality rates worldwide.New and effective antibiotics are needed to combat against bacterial resistance. Endophytic fungi are crucial reservoirs of novel bioactive metabolites. In particular, the secondary metabolites show promising therapeutic potential, notably, antibacterial. This review discussed the emerging potential of endophytic fungi as anti-MRSA agents. The ecological sources of endophytic fungi were discussed with the synthesis of bioactive metabolites.The mode of antibacterial actions was elucidated to give a better understanding of the mechanisms involved. This review may serve as an important reference for future discovery and developments of anti-MRSA agents from endophytic fungi.
5.Clinical audit of current Helicobacter pylori treatment outcomes in Singapore.
Tiing Leong ANG ; Kim Wei LIM ; Daphne ANG ; Yu Jun WONG ; Malcolm TAN ; Andrew Siang YIH WONG
Singapore medical journal 2022;63(9):503-508
INTRODUCTION:
H. pylori eradication reduces the risk of gastric malignancies and peptic ulcer disease. First-line therapies include 14-day PAC (proton pump inhibitor [PPI], amoxicillin, clarithromycin) and PBMT (PPI, bismuth, metronidazole, tetracycline). Second-line therapies include 14-day PBMT and PAL (PPI, amoxicillin, levofloxacin). This clinical audit examined current treatment outcomes in Singapore.
METHODS:
Clinical data of H. pylori-positive patientswho underwent empirical first- and second-line eradication therapies from 1 January 2017 to 31 December 2018 were reviewed. Treatment success was determined by 13C urea breath test performed at least 4 weeks after treatment and 2 weeks off PPI.
RESULTS:
A total of 963 patients (862 PAC, 36 PMC [PPI, metronidazole, clarithromycin], 18 PBMT, 13 PBAC [PAC with bismuth], 34 others) and 98 patients (62 PMBT, 15 PAL, 21 others) received first-and second-line therapies respectively. A 14-day treatment duration was appropriately prescribed for first- and second-line therapies in 65.2% and 82.7% of patients, respectively. First-line treatment success rates were noted for PAC (seven-day: 76.9%, ten-day: 88.3%, 14-day: 92.0%), PMC (seven-day: 0, ten-day: 75.0%, 14-day: 69.8%), PBMT (ten-day: 100%, 14-day: 87.5%) and PBAC (14-day: 100%). 14-day treatment was superior to seven-day treatment (90.8% vs. 71.4%; P = 0.028). PAC was superior to PMC (P < 0.001) but similar to PBMT (P = 0.518) and PBAC (P = 0.288) in 14-day therapies. 14-day second-line PAL and PBMT had similar efficacy (90.9% vs. 82.4%; P = 0.674).
CONCLUSION
First-line empirical treatment using PAC, PBMT and PBAC for 14 days had similar efficacy. Success rates for second-line PBMT and PAL were similar.
Humans
;
Helicobacter pylori
;
Clarithromycin/therapeutic use*
;
Helicobacter Infections/drug therapy*
;
Metronidazole/therapeutic use*
;
Bismuth/therapeutic use*
;
Singapore
;
Drug Therapy, Combination
;
Amoxicillin/therapeutic use*
;
Proton Pump Inhibitors/therapeutic use*
;
Anti-Bacterial Agents/therapeutic use*
;
Treatment Outcome
;
Clinical Audit
6.Functional improvement after inpatient rehabilitation in community hospitals following acute hospital care.
Htet Lin HTUN ; Lok Hang WONG ; Weixiang LIAN ; Jocelyn KOH ; Liang Tee LEE ; Jun Pei LIM ; Ian LEONG ; Wei Yen LIM
Annals of the Academy of Medicine, Singapore 2022;51(6):357-369
INTRODUCTION:
There are limited studies exploring functional improvement in relation to characteristics of patients who, following acute hospital care, receive inpatient rehabilitation in community hospitals. We evaluated the association of acute hospital admission-related factors with functional improvement on community hospital discharge.
METHODS:
We conducted a retrospective cohort study among patients who were transferred to community hospitals within 14-day post-discharge from acute hospital between 2016 and 2018. Modified Barthel Index (MBI) on a 100-point ordinal scale was used to assess functional status on admission to and discharge from the community hospital. We categorised MBI into 6 bands: 0-24, 25-49, 50-74, 75-90, 91-99 and 100. Multivariable logistic regression models were constructed to determine factors associated with categorical improvement in functional status, defined as an increase in at least one MBI band between admission and discharge.
RESULTS:
A total of 5,641 patients (median age 77 years, interquartile range 69-84; 44.2% men) were included for analysis. After adjusting for potential confounders, factors associated with functional improvement were younger age, a higher MBI on admission, and musculoskeletal diagnosis for the acute hospital admission episode. In contrast, a history of dementia or stroke; lower estimated glomerular filtration rate; abnormal serum albumin or anaemia measured during the acute hospital episode; and diagnoses of stroke, cardiac disease, malignancy, falls or pneumonia; and other chronic respiratory diseases were associated with lower odds of functional improvement.
CONCLUSION
Clinicians may want to take into account the presence of these high-risk factors in their patients when planning rehabilitation programmes, in order to maximise the likelihood of functional improvement.
Aftercare
;
Aged
;
Female
;
Hospitals, Community
;
Humans
;
Inpatients
;
Male
;
Patient Discharge
;
Retrospective Studies
;
Stroke/complications*
;
Stroke Rehabilitation
8.Subcutaneous Sarcoidosis (Darier Roussy Sarcoid): A Rare Entity of Cutaneous Sarcoidosis
Wei Cheng Leong ; Wahinuddin Sulaiman ; Ling Tze Tan ; Jyh Jong Tang
Malaysian Journal of Dermatology 2021;47(Dec 2021):95-99
Summary
Sarcoidosis is a multisystem disease characterised by granulomatous inflammation possibly due to
hyperactivation of the immune system; with unknown etiology. Subcutaneous sarcoidosis (also known
as Darier Roussy sarcoid) is a rare type of specific cutaneous lesion of sarcoidosis characterised by
multiple firm, asymptomatic to mildly tender, mobile, round to oval, and skin coloured nodules. Herein
we report a rare case of subcutaneous sarcoidosis.
Sarcoidosis
9.A SIX-YEAR TREND OF YOUTH DEPRESSION IN A HEALTHCARE GROUP IN SINGAPORE
Xiao Wei Tan ; Rajagopalan Arvind ; Eng Sing Lee ; Matthias Paul Han Sim To ; Khai Pang Leong ; Phern Chern Tor ; Daniel Shuen Sheng Fung
ASEAN Journal of Psychiatry 2021;22(8):1-8
Aim:
To examine the trend of youth depression diagnosed in a healthcare group in Singapore over a 6-year period.
Methods:
This is a retrospective analysis of the medical records of patients who had been diagnosed with depression from Jan 2013 to Dec 2018 in a healthcare group in Singapore. The yearly trend of depression diagnosis among the youths (10-24 years of age) was compared with adults (25-64 years of age) and the elderly (≥ 65 years of age). The mean age at diagnosis, distribution of gender, ethnicity and clinical care settings among the subgroup of youth patients were compared across the years using analysis of variance or Pearson’s chi-square test.
Results:
A total of 4701 youths, 15243 adults and 6908 elderly patients were included in the analysis. Between 2013 and 2018, the rise in depression diagnosis in the youth was greater than in the adult and elderly populations, and the mean age at diagnosis decreased from 49.7 ± 0.3 (mean ± SE) years in 2013 to 39.6 ± 0.3 years in 2018. Among the youths, more females had been diagnosed with depression than males and females displayed a larger increase in diagnosis of depression. There was also a larger
increase in the diagnosis of depression in primary care compared to emergency departments, outpatient specialist clinics and in-hospital wards.
Conclusion
Youth depression is a major health problem in Singapore. There is a need for the expansion of resources in a variety of avenues for depressed youths to seek help.
10.Chapter of Gastroenterologists professional guidance for management of patients with liver disease in Singapore during the COVID-19 pandemic.
Jason Pik Eu CHANG ; Yu Jun WONG ; Wei Lyn YANG ; Kieron Boon Leng LIM ; Poh Seng TAN ; Gim Hin HO ; Benjamin Cherng Hann YIP ; James Weiquan LI ; Chern Hao CHONG ; David Eng Hui ONG ; Tju Siang CHUA ; Charles Kien Fong VU ; Kok Ann GWEE ; Tiing Leong ANG ; Chee Kiat TAN
Singapore medical journal 2020;61(12):619-623
In this paper, we aim to provide professional guidance to clinicians who are managing patients with chronic liver disease during the current coronavirus disease 2019 (COVID-19) pandemic in Singapore. We reviewed and summarised the available relevant published data on liver disease in COVID-19 and the advisory statements that were issued by major professional bodies, such as the American Association for the Study of Liver Diseases and European Association for the Study of the Liver, contextualising the recommendations to our local situation.
COVID-19/epidemiology*
;
Carcinoma, Hepatocellular/therapy*
;
Chronic Disease
;
Hepatitis B, Chronic/therapy*
;
Hepatitis C, Chronic/therapy*
;
Humans
;
Liver Cirrhosis/therapy*
;
Liver Diseases/therapy*
;
Liver Neoplasms/therapy*
;
Liver Transplantation
;
Singapore/epidemiology*


Result Analysis
Print
Save
E-mail